Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea [hydroxycarbamide] Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma.

Trial Profile

Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea [hydroxycarbamide] Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Hydroxycarbamide; Imatinib
  • Indications Glioblastoma
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms AMBROSIA
  • Most Recent Events

    • 15 Apr 2011 Results of an analysis (n=101) that examined the prognostic and predictive value of platelet-derived growth factor alpha protein expression published in the International Journal of Cancer.
    • 01 Sep 2008 Results presented at the European Society for Medical Oncology.
    • 01 Sep 2008 Primary endpoint 'progression-free survival rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top